Yang Yong, Sun Ji-Han, Tan Xiao-Yu, Lu Cai-De, Huang Zhi-Ping, Zhu Hong-Da, Shi Xiao-Ting, Chen Jian-Xiong, Fang Jiong-Ze
Department of Hepatopancreatobiliary Surgery, Ningbo Medical Centre Lihuili Hospital, Ningbo University, Ningbo, 315040, Zhejiang, China.
Department of Hepatopancreatobiliary Surgery, General Hospital of Southern Theater Command, Guangzhou, 315000, China.
Dig Dis Sci. 2023 Jun;68(6):2768-2777. doi: 10.1007/s10620-023-07857-w. Epub 2023 Feb 15.
Salvage liver transplantation (sLT) is considered an effective method to treat hepatocellular carcinoma (HCC) recurrence. This multicenter research aimed to identify the prognostic factors associated with recurrence-free survival (RFS) and overall survival (OS) after sLT.
A retrospective analysis of 114 patients who had undergone sLT for recurrent HCC between February 2012 and September 2020 was performed. The baseline and clinicopathological data of the patients were collected.
The 1-, 3-, and 5-year RFS rates after sLT were 88.9%, 75.2%, and 69.2%, respectively, and the OS rates were 96.4%, 78.3%, and 70.8%. A time from liver resection (LR) to recurrence < 1 year, disease beyond the Milan criteria at sLT and macrotrabecular massive (MTM)-HCC were identified as risk factors for RFS and were further identified as independent risk factors. A time from LR to recurrence < 1 year, disease beyond the Milan criteria at sLT and MTM-HCC were also risk factors for OS and were further identified as independent risk factors.
Compared with primary liver transplantation (pLT), more prognostic factors are available from patients who had undergone LR. We suggest that in cases of HCC recurrence within 1 year after LR, disease beyond the Milan criteria at sLT and MTM-HCC patients, sLT should be used with caution.
挽救性肝移植(sLT)被认为是治疗肝细胞癌(HCC)复发的有效方法。这项多中心研究旨在确定与sLT术后无复发生存期(RFS)和总生存期(OS)相关的预后因素。
对2012年2月至2020年9月期间因复发性HCC接受sLT的114例患者进行回顾性分析。收集患者的基线和临床病理数据。
sLT术后1年、3年和5年的RFS率分别为88.9%、75.2%和69.2%,OS率分别为96.4%、78.3%和70.8%。肝切除(LR)至复发时间<1年、sLT时疾病超出米兰标准以及大结节型巨块型(MTM)-HCC被确定为RFS的危险因素,并进一步被确定为独立危险因素。LR至复发时间<1年、sLT时疾病超出米兰标准以及MTM-HCC也是OS的危险因素,并进一步被确定为独立危险因素。
与原位肝移植(pLT)相比,接受过LR的患者有更多的预后因素可供参考。我们建议,对于LR后1年内复发的HCC患者、sLT时疾病超出米兰标准的患者以及MTM-HCC患者,应谨慎使用sLT。